Citation Impact
Citing Papers
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
2015
Colorectal cancer statistics, 2020
2020 Standout
Cancer statistics, 2022
2022 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials
2022
Cancer statistics, 2023
2023 Standout
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
2019 Standout
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
2014
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
2014
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
2015
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
2015
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Cancer statistics, 2017
2017 Standout
Cancer statistics for the US Hispanic/Latino population, 2021
2021
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Breast cancer statistics, 2019
2019 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Cancer Statistics, 2021
2021 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Evidence for overuse of medical services around the world
2017
Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis
2011
The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis
2016
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Breast cancer
2016 Standout
Short-term and long-term effects of caesarean section on the health of women and children
2018 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Nomograms in oncology: more than meets the eye
2015 Standout
Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment
2017 StandoutNobel
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics
2012
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system
2019
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
2015
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
2015
Time to Treatment: Measuring Quality Breast Cancer Care
2016
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes
2019
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Survival Benefit of Radical Prostatectomy in Lymph Node–Positive Patients with Prostate Cancer
2010
Bladder cancer
2016 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Urbanisation and health in China
2012 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
2010
Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma
2014
Growth Kinetics of Renal Masses: Analysis of a Prospective Cohort of Patients Undergoing Active Surveillance
2011
How the ageing microenvironment influences tumour progression
2019
Racial/Ethnic Disparities in Time to a Breast Cancer Diagnosis
2015
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Targeting autophagy in cancer
2017 Standout
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
2011
Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
2012
Health policy reform in China: Lessons from Asia
2009
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Association between the time to surgery and survival among patients with colon cancer: A population-based study
2017
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population
2018
Management of Side Effects of Androgen Deprivation Therapy
2011
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Rationale for Percutaneous Biopsy and Histologic Characterisation of Renal Tumours
2012
Projections of the Cost of Cancer Care in the United States: 2010-2020
2011 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Molecular biology and targeted therapies for urothelial carcinoma
2015
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Racial disparities in the screening mammography continuum within a heterogeneous health care system
2023
Hepatocellular Carcinoma
2019 Standout
Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer
2021
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
2015
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
2014
Breast Cancer Statistics, 2022
2022 Standout
Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity
2022
Bladder Cancer
2020 Standout
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
2016
Population-Based Study Evaluating and Predicting the Probability of Death Resulting From Thyroid Cancer and Other Causes Among Patients With Thyroid Cancer
2012
Breast Cancer Treatment
2019 Standout
Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis
2018
Cancer statistics for Hispanics/Latinos, 2015
2015
Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women
2020
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
2015
Prostate cancer screening in African American men: a review of the evidence
2023
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
2017
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2016
2016 Standout
Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status
2013
The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth
2009 Standout
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
2011
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview
2020
Cancer treatment and survivorship statistics, 2019
2019 Standout
Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics
2017
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
2014
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Delays in radical cystectomy for muscle‐invasive bladder cancer
2019
7-Year Oncological Outcomes After Laparoscopic and Open Partial Nephrectomy
2009
Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
2017
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
2009
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
2020
Breast cancer statistics, 2017, racial disparity in mortality by state
2017
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer
2014
Racial Differences in Time to Breast Cancer Surgery and Overall Survival in the US Military Health System
2019
Second-Line Systemic Therapy for Metastatic Urothelial Carcinoma of the Bladder
2013
Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013
2017
Works of Yu‐Ning Wong being referenced
Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
2012
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
2012
Positive Experience with Medical Savings Accounts in Singapore
1995
Advanced Imaging Modalities in Early Stage Breast Cancer: Preoperative Use in the United States Medicare Population
2012
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
2009
Pathologic Concordance of Sporadic Synchronous Bilateral Renal Masses
2008
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
2015
The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer
2009
Cost implications of new treatments for advanced colorectal cancer
2009
Time to diagnosis and breast cancer stage by race/ethnicity
2012
Predicting growth of solid renal masses under active surveillance
2008
Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions
2012
Reply to J. Lagro et al and G. Lughezzani et al
2010
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors
2015
Age, Tumor Size and Relative Survival of Patients With Localized Renal Cell Carcinoma: A Surveillance, Epidemiology and End Results Analysis
2008
Time to Surgery and Breast Cancer Survival in the United States
2015
Interpreting the Economic Literature in Oncology
2007
Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System
2022
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
2014
Preoperative Delays in the US Medicare Population With Breast Cancer
2012
Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer
2008
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
2015
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
2016
The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer
2012
Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study.
2012
Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer
2014
Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram
2009
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
2014
Histopathological Characteristics of Localized Renal Cell Carcinoma Correlate With Tumor Size: A SEER Analysis
2008
Muscle-invasive urothelial bladder cancer: an update on systemic therapy
2015
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
2012